According to Bloomberg, Lantheus Holdings (LNTH), a company focused on radiopharmaceuticals, is evaluating a potential sale following a takeover offer from private equity-backed Curium Pharma . The offer values the radiopharmaceutical giant at approximately $7 billion , and if the deal goes through, it would be one of the most significant mergers and acquisitions in the global nuclear medicine field in 2026.

Lantheus Holdings, headquartered in Massachusetts, USA, is one of the oldest companies in the radiopharmaceutical field, with its origins tracing back to New England Nuclear, founded in 1956. Over the decades, Lantheus has transformed from a traditional SPECT drug supplier into a platform company centered on PET radiodiagnostics . The company's full-year revenue reached $1.54 billion in 2025, and its revenue for the first quarter of 2026 was $377.3 million.

Lantheus' flagship product, PYLARIFY (piflufolastat F 18) , was the world's first radiodiagnostic drug to surpass $1 billion in annual sales, used for PSMA PET imaging in prostate cancer. However, with increasing competition and changes in US healthcare payment policies, the product is facing pricing pressure—sales for the full year of 2025 are projected at $989 million, a 6.5% year-over-year decrease.

To address these challenges, Lantheus is simultaneously pushing forward with the launch of the new formulation of PYLARIFY (PYLARIFY TruVu), with rollout expected to begin in the fourth quarter of 2026. Furthermore, through the acquisitions of Life Molecular Imaging and Evergreen Theragnostics, the company is expanding its pipeline into Alzheimer's disease diagnostics and neuroendocrine tumor treatment. In early 2026, the company also completed the divestiture of its legacy SPECT business, further focusing on the high-growth PET radiological diagnostics sector.
The acquiring company, Curium Pharma, is equally formidable. It is one of the world's largest independent platforms in the field of nuclear medicine , with approximately 3,000 employees and providing radiotracers to 14 million patients annually. Curium is controlled by the UK-based private equity firm CapVest Partners, and in November 2025, it completed a restructuring of a continuation fund valued at $7 billion, with participation from internationally renowned investment institutions such as TPG, ICG, and CVC Capital.

It's worth noting that this isn't the first time Curium and Lantheus have crossed paths . They already have a collaborative relationship—Curium is responsible for the development and commercialization of piflufolastat F18 in Europe and previously included PYLARIFY in its US ECLIPSE clinical trial. This existing collaborative foundation may have facilitated Curium's acquisition offer.

Lantheus's decades of expertise in radiopharmaceutical production and distribution networks is a strategic asset that Curium values. For Curium, acquiring Lantheus not only grants it access to the commercially viable blockbuster drug PYLARIFY and its distribution channels, but also brings Lantheus's Alzheimer's disease diagnostic pipeline and neuroendocrine tumor treatment assets under its control, achieving an integrated diagnostic and treatment strategy.

Lantheus and Curium have been discussing a potential deal for several weeks, but no final decision has been made, and there is no guarantee that an agreement will be reached. If the deal proceeds smoothly, it is expected to be finalized within a few weeks.

In conclusion , Curium's acquisition offer for Lantheus signifies that the radiopharmaceutical sector is shifting from single-product breakthroughs to platform consolidation . With Novartis' Pluvicto validating the commercial potential of radioligand therapy with $642 million in quarterly sales, radiopharmaceutical platforms possessing manufacturing capabilities, regulatory experience, and global networks are becoming core targets for capital investment.

https://news.yaozh.com/archive/48151.html